drugset / Trial / NCT01693445
S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer
Phase 1
Completed
22 enrolled
Hallym University Medical Center
HK inno.N Corporation · collabHandok Inc. · collabJeil Pharmaceutical Co., Ltd. · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will attempt to determine the feasibility of combination of Oxaliplatin, Irinotecan, and S-1, the maximum tolerated dose and the recommended doses of the agents used, and to preliminarily evaluate the antitumor activity in untreated patients with advanced gastrointestinal cancer.
Timeline
- Start
- 2012-06
- Primary completion
- 2014-02
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 120 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 60 mg/m2 | Oral |